<DOC>
	<DOCNO>NCT00274040</DOCNO>
	<brief_summary>Comparison 18 mcg Tiotropium Inhalation Capsules ipratropiumMetered Dose Inhaler ( 2 puff 20 mcg , four time daily ) Double-Blind , Double-dummy , Efficacy Safety Study Adults Chronic Obstructive Pulmonary Disease ( COPD ) . The objective study compare bronchodilator efficacy safety tiotropium inhalation capsule ( 18 mcg daily ) ipratropium MDI ( 2 puff 20 mcg q.i.d . ) patient chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Comparison Tiotropium Ipratropium Double-Blind , Double-dummy , Efficacy Safety Study Adults With COPD</brief_title>
	<detailed_description>This 2-treatment , randomize , double-blind , parallel design trial adult patient COPD . Each dose tiotropium placebo consist one capsule self administer HandiHaler device daily treatment period ( tiotropium placebo ) . Each dose take time morning 08:00 a.m. 10:00 a.m. Each dose ipratropium MDI placebo MDI consist 2 puff ; patient inhale 2 puff four time daily . The first dose take time morning 08:00 a.m. 10:00 a.m. ; subsequent dose take lunch , dinner go bed . Study Hypothesis : The null hypothesis difference mean response tiotropium ipratropium . The alternative hypothesis difference mean response tiotropium ipratropium . Comparison ( ) : This multi-center , randomize , double-blind , double-dummy , parallel group trial compare bronchodilator efficacy safety Tiotropium ( 18 mcg day ) ipratropium Metered Dose Inhaler ( 2 puff 18 mcg four time day ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion Criteria 1 . All patient must diagnosis chronic obstructive pulmonary disease accord follow criterion : Patients must relatively stable airway obstruction FEV1 &gt; = 65 % predict normal FEV1 70 % FVC . `` Predicted normal value base formula supply individual study site . '' 2 . Male female patient 40 year age old . 3 . Patients must smoke history 10 packyears . A packyear defined equivalent smoke one pack cigarettes per day year . 4 . Patients must able perform pulmonary function test require protocol . 5 . Patients must able inhale medication HandiHaler device good technique inhale aerosol administer MDI . 6 . All patient must sign Informed Consent Form prior participation trial i.e. , prior prestudy washout usual pulmonary medication Exclusion Criteria 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients clinically significant abnormal baseline hematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion exclude . 3 . All patient SGOT SGPT twice normal range , bilirubin 150 % creatinine 125 % normal range exclude regardless clinical condition . Repeat laboratory evaluation conduct subject . 4 . Patients recent history ( i.e . one year less ) myocardial infarction . 5 . Patients recent history ( i.e . three year less ) heart failure patient cardiac arrhythmia require drug therapy . 6 . Patients regular use daytime oxygen therapy . 7 . Patients know active tuberculosis . 8 . Patients history cancer within last five year . Patients treat basal cell carcinoma allow . 9 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . 10 . Patients undergone pulmonary resection thoracotomy reason . 11 . Patients upper respiratory tract infection past 6 week prior Screening Visit ( =Visit 1 ) baseline period 2weeks ( runin period ) . 12 . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system MDI 13 . Patients know symptomatic prostatic hypertrophy bladder neck obstruction . 14 . Patients know narrowangle glaucoma . 15 . Patients treat cromolyn sodium nedocromil sodium . 16 . Patients treat antihistamine . 17 . Patients use oral corticosteroid medication unstable ( i.e . le 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 18 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( e.g . oral contraceptive , intrauterine device , diaphragm ) . 19 . Patients history asthma , allergic rhinitis atopy blood total eosinophil count 400 &gt; = per mcl ( male ) 320 &gt; = per mcl ( female ) . A repeat eosinophil count conduct patient . 20 . Patients history and/or active alcohol drug abuse . 21 . Patients take investigational drug one month six halflives ( whichever great ) prior Screening Visit ( =Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>